# Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients

> **NCT02324842** · NA · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 45 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Canagliflozin
- **DRUG:** Liraglutide

## Key facts

- **NCT ID:** NCT02324842
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2018-03-28
- **Final completion:** 2019-03-31
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2019-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02324842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02324842, "Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02324842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*